Leishmaniasis Clinical Trial
— LeishmARPsOfficial title:
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
NCT number | NCT06307171 |
Other study ID # | 2023-11 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 22, 2023 |
Est. completion date | November 2026 |
Verified date | March 2024 |
Source | IRCCS Sacro Cuore Don Calabria di Negrar |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples. General objectives of the study are: to identify specific biomarkers in order to develop more accurate serological tests for the screening of Leishmania infections that does not present cross-reaction with other infectious diseases; to unveil the Antigen Recognition Patterns (ARPs) of Leishmania infection in humans; to verify whether the ARPs and the new biomarkers are common to different Leishmania infantum strains isolated in Italy as well as in other part of the World and to different strains of L. donovani isolated in Sudan as well as in other part of the World and discard any possible cross reaction with other infectious diseases such as Chagas, TB, leprosy or malaria.
Status | Recruiting |
Enrollment | 170 |
Est. completion date | November 2026 |
Est. primary completion date | November 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | CASES: Inclusion criteria: - Leishmania positive patient from Italy (n=30) and from Sudan (n=30); - patient with a clinically or laboratory confirmed diagnosis of leishmaniasis; - signed informed consent (criteria not applied in case of samples stored at the Tropica Biobank at the DITM) - being clinically classified as leishmaniasis patient by an experienced clinician or being laboratory confirmed as leishmaniasis patients, giving positive to at least two different serological tests or to a molecular test for Leishmania sp. - adult subjects (equal or older than 18 years) Exclusion criteria: - lack of the necessary data and/or of biological samples - subjects younger than 18 years COMMUNITY CONTROLS: Inclusion criteria: - Cryo-preserved serum samples stored at the Tropica Biobank at the DITM , IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Vr), from subject from Italy (n=30) and from Africa (n=30) with no infection due by Leishmania spp. - signed informed consent to Tropica Biobank - adult subjects (equal or older than 18 years) - being negative to two different serological tests for leishmaniasis Exclusion criteria: - subjects younger than 18 years - being positive to one serological tests for leishmaniasis. VALIDATION CONTROLS (VC): Inclusion criteria: - serum samples stored in Tropica Biobank at the DITM from subjects that have been clinically diagnosed with Chagas's disease, or TB, or malaria or leprosy. - informed consent signed to Tropical Biobank - adult subjects (equal or older than 18 years) - being negative to two different serological tests for leishmaniasis. - being clinically diagnosed with Chagas disease or TB, or malaria or leprosy Exclusion criteria: - younger than 18 years - positive result to one serological test for leishmaniasis. |
Country | Name | City | State |
---|---|---|---|
Italy | IRCCS Sacro Cuore Don Calabria hospital | Negrar | Verona |
Lead Sponsor | Collaborator |
---|---|
IRCCS Sacro Cuore Don Calabria di Negrar |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Biomarkers from Leishmania spp | Presence/Absence of a reactive immunogenic band or a pattern of reactive immunogenic bands in an in-house Western blot, specific for Leishmania cases respect to negative controls. | Baseline | |
Secondary | ARPs in different Leishmania infantum and L. donovani strains | Presence/Absence of a common or differential reactive immunogenic band/pattern in different Leishmania infantum and Leishmania donovani strains from different geographical areas. | Baseline | |
Secondary | Cross reaction | Presence/Absence of cross-reaction of the identified immunogenic bands, testing serum samples of patients with malaria or TB or leprosy or Chagas' disease | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT04504435 -
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
|
Phase 1 | |
Completed |
NCT00004755 -
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
|
Phase 2 | |
Completed |
NCT00657618 -
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
|
Phase 1/Phase 2 | |
Completed |
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A | |
Recruiting |
NCT00344188 -
Diagnosis and Treatment of Leishmania Infections
|
||
Active, not recruiting |
NCT03009422 -
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
|
N/A | |
Recruiting |
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
||
Completed |
NCT01751048 -
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
|
Phase 1 | |
Terminated |
NCT06124144 -
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
|
Phase 1 | |
Completed |
NCT00662012 -
Sodium Stibogluconate Treatment of Leishmaniasis
|
Phase 2 | |
Completed |
NCT03993093 -
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
|
||
Recruiting |
NCT03784248 -
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
|
||
Withdrawn |
NCT02429505 -
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|
||
Completed |
NCT01377974 -
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
|
Phase 2 | |
Completed |
NCT02656797 -
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT01484548 -
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT01300975 -
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT00401297 -
Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes
|